Japan's troubled automaker Nissan banks on hybrid EV technology
Reporters try out Nissan's e-Power electrification technology on the current Qashqai model at the company's Grandrive facility in Yokosuka, Japan, outside Tokyo, Monday, May 26, 2025. (AP Photo/Yuri Kageyama)
YOKOSUKA, Japan — Money-losing Japanese automaker Nissan is banking on its latest 'e-Power' technology for a turnaround.
A kind of hybrid, e-Power comes equipped with both an electric motor and gasoline engine, much like the Toyota Motor Corp. Prius. It's different from a Prius in that it doesn't switch back and forth between the motor and engine during the drive.
That means the car always is running on its EV battery, ensuring a quiet, smooth ride.
'Nissan has a proud history of pioneering innovative technology that set us apart,' Chief Technology Officer Eiichi Akashi told reporters on the sidelines of a test drive at its Grandrive course outside Tokyo.
The advantage of e-Power vehicles is that they never need to be charged like EVs do. The owner just fuels up at a gas station and the car never runs out of a charge.
Nissan Motor Corp., which racked up a $4.5 billion loss for the fiscal year through March, sorely needs a hot-seller, especially in the lucrative North American market. But the U.S. market is proving a big headache for all the Japanese automakers because of President Donald Trump's tariff policies.
To achieve a turnaround, Nissan is working on reducing costs, strengthening business partnerships and redefining its lineup. That's where e-Power fits in, according to Akashi.
Yokohama-based Nissan announced earlier this month that it's slashing about 15% of its global work force, or about 20,000 employees, and reducing the number of its auto plants to 10 from 17, under an ambitious recovery plan led by its new Chief Executive Ivan Espinosa.
Nissan officials did not give a price for the upcoming e-Power models. The only other automaker offers a similar technology is 'kei,' or tiny car manufacturer Suzuki Motor Corp.
E-Power is already offered on the Nissan Qashqai and X-Trail model in Europe, and the Note in Japan. The upgraded version will be offered in the new Rogue in the U.S.
Nissan, a pioneer in EVs with its Leaf, which went on sale in 2010, is also preparing beefed up EV models. It's also working on a solid-state battery which is expected to replace the lithium-ion batteries now widely used in hybrids, EVs and e-Power models.
Analysts say Nissan is in danger of running out of cash and needs a partner. Speculation is rife its Yokohama headquarters building will get sold, or one of its Japan plants will be turned into a casino.
Nissan started talks last year with Japanese rival Honda Motor Co. for a business integration but announced in February that it was dropping the talks.
Yuri Kageyama, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
3 hours ago
- Japan Forward
How Sustainability is Reshaping the Motorsports Industry
Sustainability and motorsports? At first glance, the two words seem almost incompatible. After all, auto racing has long been synonymous with speed, roaring engines, and clouds of carbon emissions. But a championship born in Britain is turning that perception on its head. Launched in 2014, Formula E is the world's first all-electric, single-seater motorsport, demonstrating that top-tier performance and environmental responsibility can go hand in hand. Designed to accelerate innovation in electric mobility, the series has become a global testbed for sustainable technologies. From tire recycling to low-emission logistics and clean energy use, Formula E sets a new benchmark for green racing. Amplifying this revolution are Japanese firms, harnessing the sport's platform to showcase cutting-edge technologies. Yamaha Motor Company Ltd, known for its motorcycles and robotics, has partnered with Team Laura Yamaha ABT to supply electric powertrains used to propel race cars. They also provide advanced energy management systems to extend range and enhance efficiency in electric vehicles. Teijin Limited, a leader in advanced materials and chemicals, is another example. Utilizing aramid technology, the company provides Team Envision with flame-resistant racing suits that withstand temperatures up to 400°C. Teijin's Tenax™ carbon fiber is also used in the world's first two-seater Formula E car, offering a lighter, more energy-efficient structure without compromising strength or speed. Team Envision showcases its race car and suit at an event in Tokyo. (©Kenji Yoshida) Meanwhile, TDK Corporation, a multinational electronics company, is collaborating with NEOM McLaren to deliver components like multilayer ceramic chip capacitors (MLCCs), voltage control systems, and temperature sensors. These technologies are crucial for regulating power and minimizing heat and signal interference under the extreme demands of electric racing. Leveraging the high-stakes environment of motor racing, these firms are stress-testing their equipment for real-world applications. The push for sustainability in Formula E isn't limited to suppliers, however. Manufacturers and racing teams themselves are integrating climate action into their core missions. Nissan Motor Corporation, the only Japanese automaker to field its own team, sees the championship as an extension of its electric vehicle strategy. "Formula E helps us accelerate transformation for road cars while promoting climate goals through specialized R&D and technical learning," said Tommaso Volpe, managing director of the Nissan Formula E team. Nissan's Tommaso Volpe signs an autograph for a fan in Tokyo (©Kenji Yoshida) Nissan is joined by an expanding lineup, including Jaguar TCS Racing, which is leading the way in using recycled components and circular economy principles. Andretti Global is also contributing to the shift, partnering with Porsche to develop energy-efficient racing technologies. Even teams not backed by traditional automakers are playing an important role. Envision Racing, based in Britain's Silverstone Park, is a notable one. Tag Heuer Porsche Formula E Team's garage at the Tokyo E-Prix. (©Kenji Yoshida) In 2020, it became the first motorsports team to sign the United Nations Framework Convention on Climate Change Sports for Climate Action Framework, pledging to align its operations with the Paris Agreement. The team has operated with net-zero carbon emissions since its inception. Envision also co-hosts the Race Against Climate Change summit in Tokyo alongside Teijin, bringing together industry leaders, investors, startups, and media to foster collaboration on climate solutions. Despite the growing traction of electric motorsports, challenges remain. Public perception is one. Traditional racing fans often lament the lack of a deafening engine blast and the spectacle of burning fuel. But Formula E insiders believe the sport's appeal lies elsewhere – namely, in its performance and trailblazing rules. "The Gen4 car, launching at the end of next year, will nearly double the power of our current model," said Sylvain Filippi, Envision Racing's managing director. "We're getting closer to Formula One performance — but without the emissions." For Filippi, the mission isn't about sacrifice, but innovation. "Most people want to maintain their lifestyles. The only viable path forward is breakthrough ideas and creativity." Team Envision's Sylvain greeting fans and sponsors at the Tokyo E-Prix in May (©Kenji Yoshida) Another headwind on the horizon is the United States' withdrawal from the 2015 climate accord, a move that has raised fresh doubts about the future of coordinated global climate efforts. To this, Nissan's Volpe remains unfazed. "These political decisions come and go. What matters is having a solid strategy that allows us to adapt," he said. "Formula E is still in a phase of significant growth. Not just for us, but for motorsport as a whole, and across all territories." Formula E now boasts a near 400 million international fan base and is expected to continue its upward trajectory. After completing the two-day race in Tokyo on May 17 and 18, the 11 Formula E teams will travel to four different cities to finish the season. Author: Kenji Yoshida
National Post
21 hours ago
- National Post
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera
Article content Rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups, significantly reducing phlebotomy eligibility compared to placebo plus current standard of care, which was the primary endpoint All key secondary endpoints met with statistical significance, including a nearly three-fold reduction in the proportion of patients requiring phlebotomy and a four-fold improvement in hematocrit control in rusfertide arm compared to placebo arm, as well as improvements in patient-reported outcomes No serious adverse events considered related to rusfertide were reported Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. FDA Article content Article content NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass. — Protagonist Therapeutics, Inc. ('Protagonist') ( NASDAQ:PTGX) and Takeda ( TSE:4502/NYSE:TAK) announced detailed results from the Phase 3, randomized, placebo-controlled VERIFY study evaluating rusfertide in patients with polycythemia vera (PV), which met the primary and all key secondary endpoints. The data will be presented as a late-breaking oral presentation at the 61 st American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session (LBA3) at 2:09 pm CDT today. Article content PV is characterized by overproduction of red blood cells (erythrocytosis), which may increase blood viscosity, or thickness, potentially resulting in life threatening thrombotic events such as stroke, deep vein thrombosis and pulmonary embolism. People with PV can experience burdensome symptoms, including severe fatigue, difficulty in concentrating, night sweats and pruritus, which may negatively impact their daily functioning and quality of life. Hematocrit is the ratio of red blood cells to total amount of blood in the body. Achieving and maintaining controlled hematocrit levels of <45% is the primary treatment goal in PV to prevent thrombotic events and alleviate symptoms, but many patients still experience uncontrolled hematocrit levels with current standard of care treatments. Article content Rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic, is under evaluation in the Phase 3 VERIFY study for its potential to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV. In the study, patients dependent on frequent phlebotomy, with or without treatment with cytoreductive therapy, were randomized to receive once-weekly rusfertide or placebo, as an add-on to current standard of care treatment. Article content 'PV poses significant challenges for patients, including debilitating symptoms and the risk of serious thrombotic events, and hematocrit control is crucial to improving patient outcomes. The VERIFY study demonstrated that treatment with rusfertide controls hematocrit levels in phlebotomy-dependent patients, including patients receiving cytoreductive therapies,' said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. 'These results suggest rusfertide has the potential to become part of the standard of care treatment for patients with PV.' Article content The study met its primary endpoint, which was the proportion of patients achieving a clinical response, defined as the absence of phlebotomy eligibility during study Weeks 20-32. Study results demonstrated 76.9% of patients treated with rusfertide plus current standard of care achieved a clinical response, compared to 32.9% in the placebo plus current standard of care group (p<0.0001). 1 The response observed in the rusfertide arm was consistent across subgroups, regardless of risk status or type of concurrent cytoreductive therapy. 1 In addition, all key secondary endpoints met statistical significance in favor of the rusfertide arm compared to the placebo arm in the VERIFY study, as follows: Article content The mean number of phlebotomies was 0.5 phlebotomies per patient for those treated with rusfertide plus current standard of care compared to 1.8 phlebotomies per patient for those treated with placebo plus current standard of care during Weeks 0-32 (p<0.0001). 1 Only 27% of patients treated with rusfertide plus current standard of care required phlebotomy between Weeks 0-32, compared to 78% of patients who received placebo plus current standard of care. The mean number of phlebotomies during Weeks 0-32 in the rusfertide arm was reduced across subgroups, including risk status and use of concurrent cytoreductive therapy, versus the placebo arm. 62.6% of patients treated with rusfertide plus current standard of care maintained hematocrit levels below 45% versus 14.4% treated with placebo plus current standard of care (p<0.0001). 1 Rusfertide also showed statistically significant improvements in mean change from baseline to Week 32 in PROMIS Fatigue 2 (p<0.03) and the MFSAF Total Symptom Score 3 (p<0.03). Rusfertide is the first investigational therapy to prospectively demonstrate a statistically significant improvement in these patient-reported outcomes (PROs) of fatigue and symptom burden in patients with PV. 1 Article content Rusfertide was generally well tolerated. The majority of adverse events were low grade and non-serious and no serious adverse events considered related to rusfertide were reported. There was no evidence of increased risk of cancer in patients treated with rusfertide plus current standard of care compared to patients treated with placebo plus current standard of care at the time of the primary analysis. Cancer events were reported in one patient in the rusfertide arm (0.7%) and in seven patients in the placebo arm (4.8%). The most common treatment-emergent adverse events were localized injection site reactions (55.9%), anemia (15.9%) and fatigue (15.2%). 1 Article content 'These findings underscore rusfertide's potential as a first-in-class erythrocytosis-specific treatment for PV and validate more than a decade of scientific innovation originating from Protagonist's peptide technology platform,' said Dinesh V. Patel, Ph.D., President and Chief Executive Officer at Protagonist. 'We would like to thank all the patients, study staff and investigators for participating in the VERIFY study. We are pleased to partner with Takeda as we continue to advance rusfertide to potentially transform the standard of care in PV patients around the world.' Article content 'These promising pivotal data strongly support rusfertide's potential benefit for a broad spectrum of patients with PV who may be receiving current standard of care therapies but not achieving adequate hematocrit control,' said Phuong Khanh (P.K.) Morrow, M.D., Head of the Oncology Therapeutic Area Unit (OTAU) at Takeda. 'We look forward to receiving additional data from the VERIFY trial later this year, advancing rusfertide towards regulatory approval and continuing our collaboration with Protagonist to bring this innovative therapy to patients.' Article content Rusfertide has received Orphan Drug designation and Fast Track designation from the U.S. Food & Drug Administration (FDA). Article content Takeda will host an investor call regarding this update on Article content An on-demand replay will be made available on Takeda's website after the conclusion of the event. Article content The dial-in numbers for Protagonist's investor update on Monday, June 2nd at 5:00-6:00 am PDT/ 8:00-9:00 am EDT are: Article content US-based Investors: 1-877-300-8521 International Investors: 1-412-317-6026 Conference Call ID: 10199589 Article content The webcast link for the event can be found here: Article content A replay of the presentation will be available on the Protagonist Investor Relations Events and Presentations webpage following the event. Article content About VERIFY Article content The Phase 3 VERIFY study (NCT05210790) is an ongoing, three-part, global, randomized, placebo-controlled study evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The study is evaluating the efficacy and safety of once-weekly, subcutaneously self-administered rusfertide in patients with uncontrolled hematocrit who are phlebotomy-dependent despite current standard of care treatment, which could include hydroxyurea, interferon and/or ruxolitinib. The primary endpoint of the study was the proportion of patients achieving a response during Weeks 20-32, which was defined as the absence of 'phlebotomy eligibility.' To meet phlebotomy eligibility, patients in the study were required to have: confirmed hematocrit ≥45% that was ≥3% higher than their baseline hematocrit value, or hematocrit ≥48%. Article content All patients have completed their participation in the randomized, placebo-controlled portion of the study evaluating the efficacy and safety of rusfertide plus current standard of care versus placebo plus current standard of care and are now in the open-label portions of the study. Article content About Protagonist Article content Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application submissions to the FDA expected in 2025. Icotrokinra (formerly, JNJ-2113) is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ('IL-23R') which is licensed to JNJ Innovative Medicines ('JNJ'), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage oral drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program. Article content Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Article content This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of rusfertide and the timing of rusfertide regulatory submissions. In some cases, you can identify these statements by forward – looking words such as 'anticipate,' 'believe,' 'may,' 'will,' 'expect,' or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading 'Risk Factors' contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release. Article content Takeda Important Notice Article content For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Article content The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Article content This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects', 'forecasts', 'outlook' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Article content This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Article content Kuykendall A et al. Results From VERIFY, a Phase 3, Double-Blind, Placebo (PBO)-Controlled Study of Rusfertide for Treatment of Polycythemia Vera (PV). Oral presentation at: American Society of Clinical Oncology (ASCO) Annual Meeting, June 1, 2025. Chicago, IL. LBA3. PROMIS Fatigue Short Form 8a Total T-Score. MFSAF v4.0 Total Symptom Score 7. Article content Article content Article content Contacts Article content Protagonist Investor Relations Contact Corey Davis, Ph.D. LifeSci Advisors +1 212 915 2577 cdavis@ Article content Protagonist Media Contact Virginia Amann, Founder/CEO ENTENTE Network of Companies +1 833 500 0061 ext 1 virginiaamann@ Article content Article content
Vancouver Sun
2 days ago
- Vancouver Sun
Trump says he will double tariffs on steel and aluminum imports to 50 per cent
WASHINGTON — U.S. President Donald Trump said he will double the tariffs on steel and aluminum imports to 50 per cent next Wednesday. Trump initially announced the boosted duties on steel during a rally at U.S. Steel's Mon Valley Works—Irvin Plant near Pittsburgh Friday evening. He told a cheering crowd of steelworkers that the increased levies will 'further secure the steel industry in the United States.' 'Nobody is going to get around that,' Trump said. Start your day with a roundup of B.C.-focused news and opinion. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of Sunrise will soon be in your inbox. Please try again Interested in more newsletters? Browse here. In a post on social media after the rally, Trump said he would also be increasing tariffs on aluminum to 50 per cent. 'Our steel and aluminum industries are coming back like never before,' Trump posted. 'This will be yet another BIG jolt of great news for our wonderful steel and aluminum workers. MAKE AMERICA GREAT AGAIN!' In March, Trump put 25-per-cent tariffs on steel and aluminum imports to the United States. Trump used section 232 of the Trade Expansion Act of 1962 to impose steel and aluminum duties and said it will help bring manufacturing back to the United States. Canada is the largest steel supplier to the United States, accounting for nearly 25 per cent of all imports in 2023. About a quarter of all steel used in America is imported. Trump on Friday said he was thinking about a 40-per-cent tariff, but said 'the group' wanted it to be 50 per cent. As the duties have increased with Trump's tariffs, the government's producer price index found the price of steel products have gone up roughly 16 per cent. Economists have said tariffs on steel and aluminum during the first Trump administration were costly for American companies and consumers. Trump used national security powers to impose a 25-per-cent tariff on steel imports and a 10-per-cent tariff on aluminum imports in March 2018. Nearly a year later, the White House announced a deal had been reached to prevent 'surges' in steel and aluminum supplies from Canada and Mexico, ending the trade dispute. A report by the Washington-based Tax Foundation said during that time companies were forced to pay higher prices, and the duties resulted in the loss of about 75,000 manufacturing jobs. The Peterson Institute for International Economics found that each job saved in steel-producing industries came at a high cost to consumers — roughly $650,000 per job. The Canadian steel industry has warned the return of Trump's tariffs would bring back the disruption and harm seen in 2018. There were also job losses and production pauses in Canada. Trump announced the increased tariffs during a rally to celebrate a deal between Japan-based Nippon Steel and U.S. Steel. Trump said U.S. Steel will stay an American company, but few details of the deal have been made public. Nippon Steel issued a statement approving of the proposed 'partnership.' It's not clear if a deal has been finalized. The surge in duties on steel and aluminum imports come after the president faced his first major legal pushback against use of a different emergency power to impose sweeping tariffs on most nations in the world. The president used the International Emergency Economic Powers Act of 1977, usually referred to by the acronym IEEPA, to enact his so-called 'Liberation Day' and fentanyl-related tariffs. On Wednesday, the U.S. Court of International Trade blocked those tariffs saying Trump went beyond his authority to use IEEPA to take his trade war to the world. The following day, a federal appeals court granted the Trump administration's emergency motion for a temporary stay — allowing those tariffs to stay in place, for now. — With files from The Associated Press Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our newsletters here .
